BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
BioCentury This Week
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
Biotech indexes are tumbling after one of FDA’s last veteran leaders was pushed out by HHS Secretary RFK Jr. and the threat of tariffs weigh on a key biotech index. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the factors driving down the XBI, which has now crossed into bear market territory and the latest turmoil at FDA, now that CBER Director Peter Marks has been ousted. Plus, inflammation and immunology companies are finding ways beyond precision medicine to boost responses. BioCentury’s editors assess one approach — bispecific antibodies that block two inflammatory pathways instead of one.
View full story: https://www.biocentury.com/article/655488
00:00 - Introduction
00:51 - XBI's Return to the Bear Market
11:26 - Marks Ouster & Turmoil at FDA
18:07 - Bispecifics for I&I
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
